Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Semaglutide 2.4 mg delivered a statistically significant 20% risk reduction in major adverse cardiovascular events (MACE) with risk reductions demonstrated consistently across age, gender, ethnicity...
-
TORONTO, Dec. 06, 2022 (GLOBE NEWSWIRE) -- COMPASS, by Bespoke Metrics, has released its inaugural COMPASS Select List. This list recognizes the top subcontractors in the COMPASS Prequalification...
-
NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors...
-
- No further enrollment in EMERGE trial of vopratelimab in combination with ipilimumab based on interim analysis- - First patient dosed in SELECT trial of vopratelimab in combination with JTX-4014 in...
-
- Completed enrollment of Phase 2 EMERGE trial for the interim analysis of efficacy and biomarker data in early 2021 - - On track to initiate Phase 2 SELECT trial and Phase 1 trial for JTX-8064 in...
-
- On track to initiate Phase 2 SELECT trial in mid-2020 and present preliminary efficacy and related biomarker data from Phase 2 EMERGE trial in 2H 2020 - - Ended 2019 with $170.4 million in...
-
- Identification of a predictive biomarker – based on an 18 gene RNA signature and vopratelimab-specific threshold (TISvopra) – for the emergence of ICOS hi CD4 T cells that predicted clinical benefit...
-
New York, NY, Sept. 07, 2016 (GLOBE NEWSWIRE) -- SELECT, the preeminent black card and concierge service, announced the launch of their all-new SELECT HOTELS Travel Program. The first-of-its-kind...
-
NEW YORK, Aug. 8, 2013 (GLOBE NEWSWIRE) -- FoodFan Inc. - the social destination for discovering and sharing restaurants - launched Select, the first exclusive membership program that lets diners save...